DT Investment Partners LLC Has $4.35 Million Holdings in Sanofi SA (NYSE:SNY)

Share on StockTwits

DT Investment Partners LLC raised its stake in Sanofi SA (NYSE:SNY) by 6.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,933 shares of the company’s stock after acquiring an additional 5,487 shares during the quarter. DT Investment Partners LLC’s holdings in Sanofi were worth $4,352,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Ibex Wealth Advisors acquired a new stake in shares of Sanofi during the 2nd quarter worth approximately $25,000. Heritage Wealth Advisors grew its position in shares of Sanofi by 141.2% during the 2nd quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock worth $26,000 after buying an additional 353 shares during the period. Bessemer Group Inc. grew its position in shares of Sanofi by 292.4% during the 2nd quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock worth $29,000 after buying an additional 500 shares during the period. Prestige Wealth Management Group LLC acquired a new stake in shares of Sanofi during the 2nd quarter worth approximately $37,000. Finally, Evolution Wealth Advisors LLC acquired a new stake in shares of Sanofi during the 2nd quarter worth approximately $40,000. Hedge funds and other institutional investors own 7.04% of the company’s stock.

In related news, major shareholder Sanofi sold 172,904 shares of Sanofi stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.00% of the stock is owned by company insiders.

Several equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research report on Thursday, August 29th. Guggenheim upgraded shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Monday, September 23rd. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Thursday, August 29th. Sanford C. Bernstein assumed coverage on shares of Sanofi in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $52.00 price target for the company. Finally, Morgan Stanley upgraded shares of Sanofi from an “equal” rating to a “weight” rating in a research report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Sanofi presently has a consensus rating of “Buy” and a consensus target price of $49.50.

Sanofi stock opened at $45.86 on Friday. The company’s 50 day simple moving average is $45.85 and its 200 day simple moving average is $43.37. Sanofi SA has a fifty-two week low of $40.00 and a fifty-two week high of $47.47. The firm has a market capitalization of $114.86 billion, a price-to-earnings ratio of 14.65, a PEG ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: What is Green Investing?

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.